ADICET BIO INC (ACET)
US0070021086 - Common Stock
Taking everything into account, ACET scores 3 out of 10 in our fundamental rating. ACET was compared to 572 industry peers in the Biotechnology industry. While ACET has a great health rating, there are worries on its profitability. ACET does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year ACET has reported negative net income.
In the past year ACET has reported a negative cash flow from operations.
In the past 5 years ACET always reported negative net income.
ACET had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ACET's Return On Assets of -47.93% is in line compared to the rest of the industry. ACET outperforms 47.96% of its industry peers.
ACET has a better Return On Equity (-55.73%) than 63.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.93% | ||
| ROE | -55.73% | ||
| ROIC | N/A |
ROA(3y)-36.07%
ROA(5y)-46.69%
ROE(3y)-42.72%
ROE(5y)-63.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ACET so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ACET does not have a ROIC to compare to the WACC, probably because it is not profitable.
ACET has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ACET has more shares outstanding
ACET has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ACET has an Altman-Z score of -2.18. This is a bad value and indicates that ACET is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.18, ACET is in line with its industry, outperforming 51.86% of the companies in the same industry.
There is no outstanding debt for ACET. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.18 |
ROIC/WACCN/A
WACC10.88%
2.3 Liquidity
ACET has a Current Ratio of 10.64. This indicates that ACET is financially healthy and has no problem in meeting its short term obligations.
ACET has a better Current ratio (10.64) than 82.65% of its industry peers.
A Quick Ratio of 10.64 indicates that ACET has no problem at all paying its short term obligations.
The Quick ratio of ACET (10.64) is better than 82.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.64 | ||
| Quick Ratio | 10.64 |
3. Growth
3.1 Past
ACET shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.96%, which is quite impressive.
Looking at the last year, ACET shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)48.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.69%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, ACET will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.20% on average per year.
The Revenue is expected to grow by 167.54% on average over the next years. This is a very strong growth
EPS Next Y57.58%
EPS Next 2Y25.8%
EPS Next 3Y19.03%
EPS Next 5Y14.2%
Revenue Next Year-100%
Revenue Next 2Y152.98%
Revenue Next 3Y85.66%
Revenue Next 5Y167.54%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ACET. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACET. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ACET's earnings are expected to grow with 19.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.8%
EPS Next 3Y19.03%
5. Dividend
5.1 Amount
ACET does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ADICET BIO INC
NASDAQ:ACET (1/14/2025, 8:21:48 PM)
Premarket: 0.9092 0 (0%)0.9092
+0.03 (+3.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners62.48%
Inst Owner Change0%
Ins Owners1.58%
Ins Owner Change0%
Market Cap74.92M
Analysts82.86
Price Target6.53 (618.21%)
Short Float %4.84%
Short Ratio4.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.58%
Min EPS beat(2)2.1%
Max EPS beat(2)11.06%
EPS beat(4)4
Avg EPS beat(4)6.82%
Min EPS beat(4)2.1%
Max EPS beat(4)11.52%
EPS beat(8)4
Avg EPS beat(8)-23.82%
EPS beat(12)6
Avg EPS beat(12)-5.45%
EPS beat(16)9
Avg EPS beat(16)-2.63%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.9%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.81%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.35 | ||
| P/tB | 0.35 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.71
EYN/A
EPS(NY)-1.39
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS0
BVpS2.57
TBVpS2.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.93% | ||
| ROE | -55.73% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-36.07%
ROA(5y)-46.69%
ROE(3y)-42.72%
ROE(5y)-63.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 16.47% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.64 | ||
| Quick Ratio | 10.64 | ||
| Altman-Z | -2.18 |
F-Score6
WACC10.88%
ROIC/WACCN/A
Cap/Depr(3y)523.67%
Cap/Depr(5y)371.84%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.69%
EPS Next Y57.58%
EPS Next 2Y25.8%
EPS Next 3Y19.03%
EPS Next 5Y14.2%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y152.98%
Revenue Next 3Y85.66%
Revenue Next 5Y167.54%
EBIT growth 1Y3.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.96%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-76.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-133.08%
OCF growth 3YN/A
OCF growth 5YN/A